Skip to main content
HR 7071 116th Congress House

Accelerating Access to Critical Therapies for ALS Act

Official title: To provide for the acceleration of access to clinical therapies for the treatment of amyotrophic lateral sclerosis, and for other purposes.

Introduced: September 18, 2020 See on congress.gov
Health Congressional oversightDrug safety, medical device, and laboratory regulationDrug therapyHealth care coverage and access
More subjectsShow fewer subjects
Health programs administration and fundingHealth promotion and preventive careNeurological disordersPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 1, 2020
Referred to the House Committee on Energy and Commerce.
Jun 1, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action June 1, 2020

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Accelerating Access to Critical Therapies for ALS Act

This bill establishes a grant program, as well as a new center within the Food and Drug Administration (FDA), to facilitate access to investigational therapies for neurodegenerative diseases such as amyotrophic lateral sclerosis (i.e., ALS, also known as Lou Gehrig's disease, a progressive and fatal disease).

Specifically, the Department of Health and Human Services (HHS) must award grants for the provision of investigational drugs for ALS and other rapidly progressing neurodegenerative diseases through an expanded access (i.e., compassionate use) program. HHS may award these grants to (1) a small business that is the sponsor of an investigational new drug application, or (2) a participating clinical trial site for such a sponsor.

Additionally, HHS must establish within the FDA a Center of Excellence for Neurodegenerative Diseases. The center shall have duties and authorities similar to those of the FDA's Oncology Center of Excellence, which helps expedite the development of medical products and assists providers in requesting access to investigational drugs.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 198
All 198 Democratic 68 Republican 50
D
Clark, Katherine M.
Massachusetts · Oct 30, 2020
Garcia, Mike
· Oct 30, 2020
 R
Meuser, Daniel
Pennsylvania · Oct 30, 2020
Phillips, Dean
· Oct 30, 2020
 R
Steube, W. Gregory
Florida · Oct 30, 2020
 R
Wilson, Joe
South Carolina · Oct 30, 2020
 D
Barragán, Nanette Diaz
California · Oct 23, 2020
Bishop, Rob
· Oct 23, 2020
Duncan, Jeff
· Oct 23, 2020
 D
Pressley, Ayanna
Massachusetts · Oct 23, 2020
 D
Swalwell, Eric
California · Oct 23, 2020
 D
Lee, Susie
Nevada · Oct 20, 2020
 D
Lynch, Stephen F.
Massachusetts · Oct 20, 2020
 D
Morelle, Joseph D.
New York · Oct 20, 2020
 D
Stevens, Haley M.
Michigan · Oct 20, 2020
 D
Vargas, Juan
California · Oct 20, 2020
 D
Boyle, Brendan F.
Pennsylvania · Oct 16, 2020
 D
DeSaulnier, Mark
California · Oct 16, 2020
Lee, Barbara
· Oct 16, 2020
MALONEY, CAROLYN
· Oct 16, 2020
Roe, David
· Oct 16, 2020
 D
Schakowsky, Janice D.
Illinois · Oct 16, 2020
 D
Schiff, Adam B.
California · Oct 16, 2020
 D
Thompson, Mike
California · Oct 16, 2020
 D
Hayes, Jahana
Connecticut · Oct 13, 2020
Posey, Bill
· Oct 13, 2020
 R
Reschenthaler, Guy
Pennsylvania · Oct 13, 2020
 R
Simpson, Michael K.
Idaho · Oct 13, 2020
 D
Watson Coleman, Bonnie
New Jersey · Oct 13, 2020
Abraham, Ralph
· Oct 9, 2020
Brooks, Susan
· Oct 9, 2020
CHABOT, STEVE
· Oct 9, 2020
 D
Cohen, Steve
Tennessee · Oct 9, 2020
 D
Davis, Danny K.
Illinois · Oct 9, 2020
Ferguson, A.
· Oct 9, 2020
 D
Gallego, Ruben
Arizona · Oct 9, 2020
Gonzalez, Anthony
· Oct 9, 2020
HASTINGS, ALCEE
· Oct 9, 2020
 D
Houlahan, Chrissy
Pennsylvania · Oct 9, 2020
 R
Huizenga, Bill
Michigan · Oct 9, 2020
 D
Keating, William R.
Massachusetts · Oct 9, 2020
Rice, Kathleen
· Oct 9, 2020
 D
Slotkin, Elissa
Michigan · Oct 9, 2020
 D
Bishop, Sanford D.
Georgia · Oct 1, 2020
 D
Clarke, Yvette D.
New York · Oct 1, 2020
 D
Evans, Dwight
Pennsylvania · Oct 1, 2020
 R
Joyce, David P.
Ohio · Oct 1, 2020
 D
Krishnamoorthi, Raja
Illinois · Oct 1, 2020
 R
Mast, Brian J.
Florida · Oct 1, 2020
 R
McCaul, Michael T.
Texas · Oct 1, 2020
Page 1 of 4 Next
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 7071: Accelerating Access to Critical Therapies for ALS Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-7071/
MLA
"H.R. 7071: Accelerating Access to Critical Therapies for ALS Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-7071/.
Bluebook (legal)
H.R. 7071, 116th Cong. (2026), https://openamerica.io/bill/116-HR-7071/.
Markdown link
[H.R. 7071: Accelerating Access to Critical Therapies for ALS Act](https://openamerica.io/bill/116-HR-7071/)
Report a problem